Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer
“On behalf of the entire company and our Board of Directors, I want to thank Alan for his dedication and significant contributions and wish him well as he moves on to a new opportunity,” stated Bellicum’s President & CEO
Bellicum has initiated a search process to appoint a new CFO and Mr. Musso will provide support to the Company in a consultancy role during the transition.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: , our capital needs and uses, our intentions and abilities to continue executing on our business plan and the upcoming readouts on our clinical programs. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the
Investors: Solebury Trout
Chad Rubin646-378-2947 firstname.lastname@example.org Media: Solebury Trout Brad Miles646-513-3125 email@example.com
Source: Bellicum Pharmaceuticals, Inc.